Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 for Efficacy and Safety in Patients With CF Heterozygous for F508del-CFTR + Gating Mutation Being Treated With Ivacaftor

X
Trial Profile

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 for Efficacy and Safety in Patients With CF Heterozygous for F508del-CFTR + Gating Mutation Being Treated With Ivacaftor

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Nov 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cavosonstat (Primary) ; Ivacaftor
  • Indications Cystic fibrosis
  • Focus Proof of concept; Therapeutic Use
  • Acronyms SNO-7
  • Sponsors Nivalis Therapeutics
  • Most Recent Events

    • 25 Jul 2017 According to a Alpine Immune Sciences media release, Alpine Immune Sciences acquired Nivalis Therapeutics and the combined companies changed its name to Alpine Immune Sciences.
    • 01 May 2017 According to a Nivalis Therapeutics media release, following disappointing results of two phase II trials (SNO-6 and SNO-7) of cavosonstat in cystic fibrosis, the company has determined to not pursue the development of this drug in cystic fibrosis and to wind down its research and development activities.
    • 17 Nov 2016 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top